Alterola Biotech, Inc.
ABTIOTCHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$7443450
P/E Ratio—
52W High$0.2
52W Low$0.0002
Alterola Biotech, Inc. (ABTI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ABTI · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 21, 2023EPS Actual
-$0.00
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 21, 2023
After Market Close
ABTI reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2025 | Nov 27, 2025 | — | — | — | — | — | — |
| ◌ Q3 FY2025 | Jul 16, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Mar 5, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Feb 28, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 19, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Aug 15, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Feb 20, 2024 | — | — | — | — | — | — |
| — Q4 FY2023 | Nov 21, 2023 | — | -$0.00 | — | — | — | — |
Q4 FY2025
Nov 27, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Jul 16, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 5, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 28, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 19, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 15, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 20, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 21, 2023
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.57 | $1.57 | $1.57 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 21, 2023 | — | $0.01 | $0.01 | -2.90% |
| — Q3 FY2023 | Aug 16, 2023 | — | $0.01 | $0.01 | -8.20% |
| — Q2 FY2023 | Jun 5, 2023 | — | $0.02 | $0.02 | +25.00% |
| — Q1 FY2023 | Feb 15, 2023 | — | $0.06 | $0.06 | +0.00% |
| — Q4 FY2022 | Nov 21, 2022 | — | $0.08 | $0.08 | +0.00% |
Q4 FY2023-2.90%
Report Date
Nov 21, 2023
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q3 FY2023-8.20%
Report Date
Aug 16, 2023
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q2 FY2023+25.00%
Report Date
Jun 5, 2023
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q1 FY2023+0.00%
Report Date
Feb 15, 2023
EPS Beat/Miss
—
Price Before
$0.06
Price After
$0.06
Q4 FY2022+0.00%
Report Date
Nov 21, 2022
EPS Beat/Miss
—
Price Before
$0.08
Price After
$0.08
Beat Rate0 / 5 quarters
Largest Move+25.00% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ABTI ends December
Alterola Biotech, Inc. (ABTI) most recently reported earnings on November 21, 2023 for Q4 FY2023, posting EPS of $-0.00 (in line with the analyst consensus of —). The next ABTI earnings date is expected around September 1, 2026.
Each quarter, investors track ABTI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ABTI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ABTI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ABTI earnings · 4 questionsAlterola Biotech, Inc.'s next earnings report is expected around September 1, 2026. ABTI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ABTI historically reports after market close (AMC).
ABTI earnings datewhen is ABTI earningsABTI next earnings datewhen does ABTI report earningsABTI earnings calendar
▸ Source: FMP · Alterola Biotech, Inc. SEC filings · US GAAP · Alterola Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026